Researchers conducted an early-phase clinical trial to test the safety and initial effectiveness of a new experimental drug called ifinatamab deruxtecan. The study involved 97 adults with various advanced solid tumors, including lung, breast, and prostate cancers, that had stopped responding to standard treatments. The drug was given by IV every three weeks at different doses to find a safe level.
The main goal was to check the drug's safety. The most common serious side effects were anemia and low white blood cell counts. One patient died from a treatment-related lung condition called interstitial lung disease. In terms of effectiveness, the drug shrank tumors in 34% of the 70 patients who could be evaluated for this response.
It is important to be cautious about these results. This was a small, early-phase study designed mainly to test safety and find the right dose. There was no comparison group receiving a different treatment, so we cannot say how this drug stacks up against other options. The maximum safe dose was not even reached in this trial.
Readers should understand this is a first step in a long research process. The results are promising enough for scientists to continue studying the drug in larger groups of patients. However, it is not yet available outside of clinical trials, and its long-term benefits and risks remain unknown.